Literature DB >> 31840684

Eptinezumab for the treatment of migraine.

D Scuteri1, M T Corasaniti2, P Tonin3, G Bagetta4.   

Abstract

Eptinezumab (ALD-403) is a genetically engineered humanized IgG1kappa directed towards calcitonin gene-related peptide (CGRP), currently in late-stage clinical development. Eptinezumab targets the pathway of CGRP, importantly implicated in migraine pathophysiology, and may represent the first-to-market infusion therapy for migraine prevention. The background for its approval consists in preclinical data and clinical trials. Here, we provide a comprehensive review of molecular pharmacology, pharmacokinetics, metabolism, efficacy and safety investigated in the preclinical and clinical studies, with insight on possible future directions. Copyright 2019 Clarivate Analytics.

Entities:  

Keywords:  ALD-403; Analgesic drugs; Anti-calcitonin gene-related peptide (CGRP) treatments; Eptinezumab; Migraine; Monoclonal antibodies

Year:  2019        PMID： 31840684     DOI： 10.1358/dot.2019.55.11.3069864

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN： 1699-3993            Impact factor:   2.245


  12 in total

1.  Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double-blind, placebo-controlled trial to assess the efficacy of furocoumarin-free bergamot loaded in a nanotechnology-based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia.

Authors:  Damiana Scuteri; Giorgio Sandrini; Stefano Tamburin; Maria Tiziana Corasaniti; Pierluigi Nicotera; Paolo Tonin; Giacinto Bagetta
Journal:  Phytother Res       Date:  2021-08-26       Impact factor: 6.388

2.  Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) Pain Scale: Study Protocol.

Authors:  Damiana Scuteri; Marianna Contrada; Teresa Loria; Paolo Tonin; Giorgio Sandrini; Stefano Tamburin; Pierluigi Nicotera; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Brain Sci       Date:  2022-04-29

3.  Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions.

Authors:  Damiana Scuteri; Laura Rombolà; Michele Crudo; Chizuko Watanabe; Hirokazu Mizoguchi; Shinobu Sakurada; Kengo Hamamura; Tsukasa Sakurada; Luigi Antonio Morrone; Paolo Tonin; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

4.  Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.

Authors:  Damiana Scuteri; Maria Tiziana Corasaniti; Paolo Tonin; Pierluigi Nicotera; Giacinto Bagetta
Journal:  J Headache Pain       Date:  2021-07-30       Impact factor: 7.277

5.  ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development.

Authors:  Loris Pignolo; Paolo Tonin; Pierluigi Nicotera; Giacinto Bagetta; Damiana Scuteri
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

Review 6.  Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia.

Authors:  Damiana Scuteri; Kengo Hamamura; Chizuko Watanabe; Paolo Tonin; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

Review 7.  Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence.

Authors:  Damiana Scuteri; Francesca Guida; Serena Boccella; Enza Palazzo; Sabatino Maione; Juan Francisco Rodríguez-Landa; Lucia Martínez-Mota; Paolo Tonin; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

8.  Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia.

Authors:  Damiana Scuteri; Roberta Cassano; Sonia Trombino; Rossella Russo; Hirokazu Mizoguchi; Chizuko Watanabe; Kengo Hamamura; Soh Katsuyama; Takaaki Komatsu; Luigi Antonio Morrone; Laura Rombolà; Annagrazia Adornetto; Annarita S Laganà; Maria Tiziana Corasaniti; Paolo Tonin; Shinobu Sakurada; Tsukasa Sakurada; Pierluigi Nicotera; Giacinto Bagetta
Journal:  Pharmaceutics       Date:  2021-03-12       Impact factor: 6.321

9.  Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.

Authors:  Stephen Silberstein; Merle Diamond; Nada A Hindiyeh; David M Biondi; Roger Cady; Joe Hirman; Brent Allan; Susan Pederson; Barbara Schaeffler; Jeff Smith
Journal:  J Headache Pain       Date:  2020-10-06       Impact factor: 7.277

10.  Editorial: "Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation".

Authors:  Damiana Scuteri; Tsukasa Sakurada; Paolo Tonin; Maria Tiziana Corasaniti; Giacinto Bagetta
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.